FDA requires trials of COVID shots for healthy kids, adults

Published: Tuesday, May 20, 2025 at 9:30 pm

FDA Tightens Grip on COVID Booster Approvals: New Trials Required for Healthy Adults and Children

The Food and Drug Administration (FDA) is shaking up its approach to COVID-19 booster shots, requiring new clinical trials for updated vaccines targeting healthy adults and children. This shift, outlined in a recent article in the *New England Journal of Medicine* by FDA officials, marks a significant change in how future COVID-19 immunizations will be approved.

While booster shots will remain available for high-risk individuals, the FDA will now demand comprehensive studies from drugmakers like Moderna, Pfizer, and Novavax before approving updated vaccines for those aged 6 months to 64 years without underlying health conditions. This move adds a layer of complexity and cost for vaccine manufacturers, who may struggle to complete these trials in time for the upcoming fall immunization season.

The FDA's decision stems from uncertainty surrounding the benefits of repeated boosters, particularly for low-risk individuals who may have already been vaccinated or infected. The agency aims to balance regulatory flexibility with a commitment to rigorous scientific standards. The new policy allows for continued access to vaccines for the elderly and those with health risks, a group estimated to include between 100 and 200 million Americans, without requiring additional studies.

This change comes as vaccination rates have declined, with only 23% of U.S. adults receiving the latest booster. The FDA's approach could potentially increase vaccine usage, as many people qualify as high-risk due to conditions like obesity and mental health issues. However, the requirement for new trials for healthy individuals raises questions about the practicality and ethical considerations of withholding proven protection in placebo-controlled studies.

BNN's Perspective: This FDA decision reflects a pragmatic approach to a changing landscape. While the need for rigorous data is understandable, the potential for delays and the ethical challenges of placebo-controlled trials in the context of an existing vaccine are valid concerns. The FDA's balancing act between scientific rigor and public health access will be crucial in navigating the future of COVID-19 vaccinations.

Keywords: FDA, COVID-19, booster shots, vaccine, clinical trials, healthy adults, children, high-risk, Moderna, Pfizer, Novavax, approval, immunization, vaccination rates, regulatory, science, safety, myocarditis.

Full Story